Abstract: The present invention provides a composition having a metabolism-improving action, which comprises a supernatant of brown adipocytes or a purified product thereof. The present invention also provides a method of preparing the supernatant without using a culture solution comprising a high concentration of glucose. The present invention also provides a method of producing brown adipocytes using pluripotent stem cells, which are useful for preparing the supernatant of brown adipocytes. The present invention has succeeded in obtaining a supernatant having a metabolism-improving action from brown adipocytes. It was also possible to obtain the supernatant without using a culture solution comprising a high concentration of glucose. The present invention has also succeeded in producing brown adipocytes from pluripotent stem cells using a feeder-free culture system without adding a cytokine cocktail or the like.

Abstract: Disclosed herewith is a method for inducing angiogenesis using modified placental tissue or an extract thereof to treat conditions other than cardiovascular conditions.

Abstract: A degradation product produced by degrading a composition containing a hyaluronic acid and a protein with a protease has a pain relieving effect, a joint function ameliorating effect, a cholesterol-lowering effect, a hypoglycemic effect and a diastolic blood pressure-lowering effect.

Abstract: A functional food including a supplement composition in which the supplement composition includes a non-winterized marine source oil.

Abstract: Uses are described for hemolymph, contents of hemolymph, fragments or components of the contents found within hemolymph, including hemocyanin, any of which may be derived from crustaceans, as functional agents to treat diseases, provide symptomatic relief, provide a beautifying or relieving effect to the intended organ or site-of-intended-use, or be used as an ingredient in formulations designed to aid in the relief of pathologies or states commonly associated with inflammation and dry skin, including, but not limited to eczema, dermatitis, psoriasis, cystitis, asthma, sinusitis, joint pain, as well as other instances of acute and chronic inflammation, and for relief of general symptoms that may be associated with inflammation and dry skin but not linked directly in the intended use, including, but not limited to, redness, itchiness, irritation, muscle or joint fatigue, swelling, hydrating the skin, and reducing transepidermal water loss (TEWL).

Abstract: A method of treating a medical condition addressed by one or more cannabinoids, comprising providing the cannabinoid enriched solid composition to a recipient in an amount sufficient to treat the medical condition. A composition and a method to produce the composition are also disclosed.

Abstract: This disclosure describes novel probiotics, and also describes novel methods by which such probiotics can be obtained.

Abstract: A method for increasing gastric tract acid (GTA) production in a mammalian subject.

Abstract: The disclosure relates to composition and methods to treat dermatological diseases and disorders and to composition that modulate skin barrier permeability.

Abstract: Provided herein are compositions and methods comprising microbiome biomarkers of responsiveness/resistance to immunotherapy (e.g., anti-PD1/PD-L1 therapy), and diagnostic, prognostic and therapeutic uses thereof. In particular, the amount, identity, presence, and/or ratio of microflora in the microbiome of a subject is used to determine the responsiveness/resistance of the subject to immunotherapy, and/or the microbiome of a subject is manipulated to enhance the responsiveness of the subject to various immunotherapies and co-therapies.

Abstract: The present specification discloses an immunomodulatory composition comprising Lactobacillus-derived extracellular vesicles as an active ingredient. The Lactobacillus may be Lactobacillus plantarum. The composition has the effects of inducing differentiation into M2-type macrophages and reducing expression of at least one member selected from the group consisting of CCR2, SOCS3 and HLA-DR?, which are M1-type macrophage differentiation markers.

Abstract: Bacteriophage compositions and therapeutic uses thereof. In particular, compositions of lytic bacteriophages that are capable of lysing Propionibacterium acnes (P. acnes) bacterial strains associated with acne and biofilms, thereby treating or preventing acne and biofilms.

Abstract: Compositions and methods are provided for treating cancer comprising a composition comprising an oncolytic virus and a targeting moiety on the surface of the virus, wherein the oncolytic virus does not encode or express the targeting moiety within various aspects such compositions and methods can be used to treat a wide variety of cancers (e.g., gastrointestinal cancer, such as esophageal, stomach and colon cancers).

Abstract: Processes for producing a cannabis tincture and salve are disclosed herein. The processes include steps for cultivating the required ingredients, preparing the ingredients and combining the ingredients under predetermined conditions to form a tincture, a salve, or both. The tincture and salve are useful for providing relief from a variety of ailments and discomforts.

Abstract: A Panax plant extract and a pharmaceutical composition and the use thereof. The mass ratio of Rk1 and Rg5 in the Panax plant extract is 1:1.0-1.5, and the content of Rg3, Rg5 and Rk1 in the extract is relatively high. The extract can be used to prepare a drug for treating chronic heart failure, coronary stable angina, arrhythmia, diabetes and complications thereof, Meniere's disease, hyperlipemia, fatty liver, Alzheimer's disease, dymenorrhea, metabolic syndrome, gout, tumours or vascular leak syndrome.

Abstract: A formulation includes butterfly pea extract and cannabinoids.

Abstract: The invention relates to a synergistic composition comprising a dry extract of plant of genus Galeopsis and a compound promoting autophagy selected from biotin and R-N1-spermidine or a salt thereof, wherein R is hydrogen or methyl and mixtures thereof. The synergistic compositions according to the invention may be in the form of a topical formulation or oral formulation and is useful as a promoter of autophagy especially in cells of human scalp hair follicles and in promoting hair growth and/or in the treatment of hair thinning or hair loss.

Abstract: The present invention provides a composition of a mixture comprising Radix Aconiti, Radix Aconiti Kusnezoffii, Rhizoma et Radix Notopterygii and Radix Angelicae Pubescentis, and an herbal extract composition of a mixture comprising Radix Aconiti, Radix Aconiti Kusnezoffii, Rhizoma et Radix Notopterygii and Radix Angelicae Pubescentis. A method for preparing the herbal extract composition and a product by the method thereof is further provided by the present invention. The herbal extract composition is useful for alleviating pain and treating diseases such as rheumatoid arthritis (RA) or osteoarthritis (OA).

Abstract: A MATZHU is prepared by using leaves of Gramineae (Graminae) and Bambusoideae plant as raw materials. The MATZHU has a stable emerald color and an average powder particle size of 800 to 10,000 meshes. The MATZHU also has a total amount of dietary fiber of ?60%, a content of lignin of ?20% and a content of minerals of ?7%. The MATZHU includes at least three or more bamboo leaf characteristic components, such as orientin, isoorientin, vitexin, isovitexin, adenosine, ?-hydroxylysine and p-coumaric acid. The method for the MATZHU preparation includes, in turn, performing blanching and color protection, drying and superfine grinding the raw materials. By utilizing the thermal stability and the light stability of the MATZHU, the MATZHU may be used as a raw food material, a functional ingredient, or a dietary supplement.

Abstract: The present invention relates, in general, to a method of treating patients undergoing enzyme replacement therapy (ERT) or other therapy involving the administration of a proteinaceous therapeutic agent as well gene replacement therapy with non-viral or viral vectors, or other therapeutic modality or modalities, used alone or in combination, which involve the administration of exogenous substances for potential therapeutic benefit, including, but not limited to DNA vaccines, siRNA, splice-site switching oligomers (SSOs) as well as RNA-based nanoparticles (RNPs) and nanovaccines. The invention further relates to compounds and compositions suitable for use in such methods.

Abstract: A conjugate and preparation method therefor, comprising a medication composition comprising the conjugate and a use of the medication composition in preparing medications for the treatment or prevention of diseases.

Abstract: An object of the present invention is to provide a composition for use in improving, maintaining and/or ameliorating an attention function and/or a judgement function. According to the present invention, there is provided a composition for use in improving, maintaining and/or ameliorating an attention function and/or a judgement function, comprising an enzymatic decomposition product of milk protein as an active ingredient. The enzymatic decomposition product of milk protein is preferably an enzymatic decomposition product of whey protein. The enzymatic decomposition product of milk protein preferably comprises a peptide having an amino acid sequence of GTWY (SEQ ID NO: 1) and a peptide having an amino acid sequence of WY.

Abstract: Provided is a method for treating cancer by administering to an individual who has the cancer a MAD1 peptide. The peptide can enhance the effect of a chemotherapeutic agent that is administered to the individual in combination with the peptide.

Abstract: Disclosed herein are compositions and methods for the prevention and treatment of immune deficiency and inflammation using cyclic histidyl-proline plus zinc (Cyclo-Z). Disclosed herein are compositions that can be used to treat immune disorders and inflammation.

Abstract: Compositions that are oil-free and fat-free aqueous suspensions of cyclosporin and contain a cyclosporin (e.g., cyclosporine), a hydrophilic pharmaceutically acceptable solvent in which the cyclosporin (e.g., cyclosporine) is soluble, a dispersing agent, a suspending agent and an aqueous vehicle are disclosed. Methods of producing such compositions, as well as methods of using the compositions to treat ophthalmic disorders are also disclosed.

Abstract: Compositions that are oil-free and fat-free aqueous suspensions of cyclosporin and contain a cyclosporin (e.g., cyclosporine), a hydrophilic pharmaceutically acceptable solvent in which the cyclosporin (e.g., cyclosporine) is soluble, a dispersing agent, a suspending agent and an aqueous vehicle are disclosed. Methods of producing such compositions, as well as methods of using the compositions to treat ophthalmic disorders are also disclosed.

Abstract: Compositions that are oil-free and fat-free aqueous suspensions of cyclosporin and contain a cyclosporin (e.g., cyclosporine), a hydrophilic pharmaceutically acceptable solvent in which the cyclosporin (e.g., cyclosporine) is soluble, a dispersing agent, a suspending agent and an aqueous vehicle are disclosed. Methods of producing such compositions, as well as methods of using the compositions to treat ophthalmic disorders are also disclosed.

Abstract: The invention relates to the field of minimal residual disease (MRD) diagnostics, which is progressively more applied for the evaluation of treatment effectiveness in patients with a hematological malignancy, such as B-cell precursor acute lymphoblastic leukemia (BCP-ALL), B-cell chronic lymphocytic leukemia (B-CLL), and multiple myeloma (MM). Provided are unique reagent compositions with carefully selected and thoroughly tested combinations of antibodies, for ?8-color flow cytometric stainings as well as for 10-color and 12-color flow cyometric stainings, which can reach sensitivities of at least 10?4, even down to 10?5. Also provided are diagnostic kits and methods for detecting MRD.

Abstract: Combined preparations, and pharmaceutical compositions, comprising: (a) LAG-3 protein, or a derivative thereof that is able to bind to MHC class II molecules; and (b) a programmed cell death protein-1 (PD-1) pathway inhibitor, are described. The PD-1 pathway inhibitor, such as an anti-PD-1 antibody or an anti-PD-L1 antibody, and a soluble derivative of LAG-3, acting as an APC activator, together synergistically activate T cells (in particular, CD8+ T cells). Use of the combined preparations and compositions as medicaments, in particular for the treatment of cancer or infection, and to methods for the treatment of cancer or infection, is described.

Abstract: The present disclosure provides compositions, methods, and kits that enable the in situ growth of polymers on or within a subject. In some aspects, the monomer, dopamine, polymerizes in vivo to form a polymer on a tissue. In additional aspects, the compositions, methods, and kits are useful for treating or preventing a disease or disorder.

Abstract: The present application discloses a method for preventing or retarding degeneration of intervertebral disc at an intervertebral disc defect site, which includes injecting a mammalian connective tissue cell into the intervertebral disc defect site.

Abstract: Methods of treating and preventing metabolic disease through inhibiting interleukin 11 (IL-11)-mediated signalling are disclosed, as well as agents for use in such methods.

Abstract: The present disclosure provides compositions including an amylin receptor agonist and a beta-2-adreno-receptor agonist (e.g., an anti-hyperglycemia agent), compositions including at least two different anti-catabolic agents, compositions including at least two different anti-adiposity agents, methods of treating a condition (e.g., muscle wasting, muscle wasting-related condition, excess adiposity, an excess adiposity-related condition, and the like), methods of increasing muscle mass, formation of thermogenic brown adipose tissue (BAT), and/or decreasing white adipose tissue (WAT) content, methods of treating muscle wasting, methods of treating excess adiposity, and the like.

Abstract: The present invention relates to a CNP prodrug or a pharmaceutically acceptable salt thereof comprising a CNP moiety -D; and a carrier moiety —Z that is conjugated through a moiety -L2- to a reversible prodrug linker moiety -L1-, which reversible prodrug linker moiety -L1- is covalently and reversibly conjugated to -D; wherein -L2- is a chemical bond or a spacer; and —Z is a polymer having a molecular weight of at least 10 kDa. It further relates to pharmaceutical compositions comprising the CNP prodrug or a pharmaceutically acceptable salt thereof, their use as a medicament and to methods of treatment.

Abstract: The present application relates to novel methods for preventing, slowing the progression of, or treating nonalcoholic fatty liver (NAFL), nonalcoholic steatohepatitis (NASH), and/or liver fibrosis, and/or reducing the risks of liver cancer in subjects, such as HIV-infected subjects, using a GHRH molecule, e.g., trans-3-hexenoyl-GHRH(1-44)-NH2, or a pharmaceutically acceptable salt thereof. The subjects may have particular pathological features such as liver fibrosis, a hepatic fat fraction (HFF) of at least about 10%, serum alanine aminotransferase (ALT) levels of at least about 30 U/L, and/or a NAFLD Activity Score (NAS) of at least 4 or 5.

Abstract: The present invention relates to solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid and their use in medicine.

Abstract: Provided is a method for administering a recombinant human growth hormone GX-H9 for treating growth hormone deficiency. Particularly, the present disclosure relates to a pharmaceutical composition for treating growth hormone deficiency, containing a recombinant hGH GX-H9 and a pharmaceutically acceptable carrier, in which the recombinant GX-H9 is administered once a week with a dosage of 0.1 to 0.3 mg per weight kg of a patient or twice-monthly with a dosage of 0.1 to 0.4 mg per weight kg of the patient. Further, the present disclosure relates to a method for treating growth hormone deficiency including administering an recombinant hGH GX-H9 to a patient with growth hormone deficiency once a week with a dosage of 0.1 to 0.3 mg per weight kg of the patient or twice-monthly with a dosage of 0.1 to 0.4 mg per weight kg of the patient.

Abstract: Disclosed herein are methods and compositions for treatment of neurological-related disorders, and pain syndrome associated with disorders using botulinum toxin targeted to nerve ganglia.

Abstract: Disclosed herein are methods and compositions for treatment of skin disorders and diseases using botulinum toxin targeted to nerve ganglia.

Abstract: A method, composition, and kit for treating a malarial infection in a subject by using an enzyme conjugate comprising a variant cystathione-gamma-lyase and a targeting ligand which binds to erythrocytes infected with Plasmodium pathogens. The variant cystathione-gamma-lyase has methioninase activity. Also disclosed is a method of treating Plasmodium-infected blood by exposing the infected blood with the enzyme conjugate.

Abstract: The present invention provides a clinically applicable method of stem cell transplantation that facilitates engraftment and reconstitutes immunocompetence of the recipient without requiring radiotherapy or chemotherapy, and without development of GVHD or graft rejection.

Abstract: Methods for preparing antigen-loaded dendritic cells (DCs) for treatment of cancer in a subject are provided, using an electroporation apparatus having an electroporation chamber including an upper electrode, a lower electrode and a path defined in the electroporation chamber. The electroporation apparatus includes a first input allowing passage of DCs into the electroporation chamber and a first output allowing passage of antigen-loaded DCs from the electroporation chamber. The first input and the first output are separated by an offset distance. Methods of treating cancer by administering antigen-loaded DCs are also provided.

Abstract: The present invention relates to engineered cells, engineered chimaeric antigen ligands (CALs), and novel uses of multi-specific binding agents for bridging cells. The invention also provides variation-matched engineered cells.

Abstract: A composition for administration to a subject is disclosed and the composition comprises a vaccine and plinabulin without or with an adjuvant to induce, enhance or boost humoral response. A method of treatment by administering a vaccine and plinabulin is disclosed. A method of enhancing an immune response to a vaccine in a subject by administering to the subject a vaccine and plinabulin is also disclosed. The vaccine and plinabulin can be administered concurrently or separately.

Abstract: This invention relates to non-human immune cells for universal chimeric antigen receptor and related immune cell therapies.

Abstract: Disclosed herein relates to immunotherapeutic compositions comprising immunotherapeutic peptides comprising neoepitopes, polynucleotides encoding the immunotherapeutic peptides, antigen presenting cells comprising the immunotherapeutic peptides or polynucleotides, or T cell receptors specific for the neoepitopes. Also disclosed herein is use of the immunotherapeutic compositions.

Abstract: Provided herein are tumor-associated antigen peptides comprising heteroclitic mutations and fusion polypeptides comprising such heteroclitic peptide. Also provided are nucleic acids encoding such peptides and fusion polypeptides, recombinant bacteria or Listeria strains comprising such peptides, fusion polypeptides, or nucleic acids, and cell banks comprising such recombinant bacteria or Listeria strains. Also provided herein are methods of generating such peptides, fusion polypeptides, nucleic acids, and recombinant bacteria or Listeria strains. Also provided are immunogenic compositions, pharmaceutical compositions, and vaccines comprising such peptides, fusion polypeptides, nucleic acids, or recombinant bacteria or Listeria strains.

Abstract: A vaccine platform using a Yersinia pestis mutant synthesizing an adjuvant form lipid A (monophosphoryl lipid A, MPLA) for the increased biogenesis of bacterial outer membrane vesicles (OMVs). To enhance the immunogenicity of the OMVs, an Asd-based balanced-lethal host-vector system was constructed to oversynthesize the LcrV antigen of Y. pestis, raise the amounts of LcrV enclosed in OMVs by Type II secretion system, and eliminate harmful factors like plasminogen activator (Pla) and murine toxin from the OMVs. Vaccination with OMVs containing MPLA and increased amounts of LcrV with diminished toxicity afforded complete protection in mice against subcutaneous challenge and intranasal challenge and was significantly superior to that resulting from vaccination with LcrV/alhydrogel. Additionally, the Yersinia OMV can be used as a platform to deliver the heterologous antigens of Bacillus anthraces.

Abstract: The invention is related to multivalent immunogenic compositions comprising more than one S. pneumoniae polysaccharide protein conjugates, wherein each of the conjugates comprises a polysaccharide from an S. pneumoniae serotype conjugated to a carrier protein, wherein the serotypes of S. pneumoniae are as defined herein. In some embodiments, at least one of the polysaccharide protein conjugates is formed by a conjugation reaction comprising an aprotic solvent. In further embodiments, each of the polysaccharide protein conjugates is formed by a conjugation reaction comprising an aprotic solvent. Also provided are methods for inducing a protective immune response in a human patient comprising administering the multivalent immunogenic compositions of the invention to the patient. The multivalent immunogenic compositions are useful for providing protection against S. pneumoniae infection and diseases caused by S. pneumoniae.

Abstract: The present disclosure relates to Zika virus vaccines and immunogenic compositions having one or more antigens from a Zika virus (e.g., a Zika virus clonal isolate, a non-human cell adapted Zika virus, etc.), and methods of treatments and uses thereof.